Abstract: Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.

Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

Abstract: This invention relates to methods of increasing activity of the neurotransmitter acetylcholine in specific brain regions to treat diseases or disorders associated with reduced acetylcholine activity. In particular, the methods relate to intranasal administration of pregnenolone in only one nostril increasing acetylcholine activity only in the amygdala corresponding to this nostril, thus, providing ipsilateral increase of acetylcholine activity.

Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

Abstract: Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprises an agent that binds to one or more air pollutants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described are nasal compositions comprising an agent comprising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. The compositions also may comprise other agents, such as an immunosuppressant. Also described are methods of making and using the compositions.

Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

Abstract: The present invention relates to a two-part plastic blank set for the production of a drug applicator for storing a unit dose of a drug preparation and for administering that unit dose into the human nose.

Abstract: Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprises an agent that binds to one or more air pollutants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described are nasal compositions comprising an agent comprising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. The compositions also may comprise other agents, such as an immunosuppressant. Also described are methods of making and using the compositions.

Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.

Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained scrum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.

Abstract: Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.

Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.

Abstract: The invention relates to a filling and closing device (20) for an applicator for active substances (1) and to a method for filling and closing such an applicator for active substances (1) by means of such a filling and closing device (20). The applicator for active substances (1) comprises an applicator tube (7) that overlaps the sealing edge (5), at least in part. The filling and closing device (20) comprises a receiving element (21) for the lower part (2) of the applicator for active substances (1), having a circumferential pressure surface (22) and a receiving channel (23) for the applicator tube (7), said receiving channel extending below the pressure surface (22). The receiving element (21) is constructed of at least two parts, having a base element (24) and a cover element (25) that is movable with respect to the base element (24).

Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained scrum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.

Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.

Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.

Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.